Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Buy
52
LH Quote, Financials, Valuation and Earnings
Last price:
$238.26
Seasonality move
:
7.07%
Day range:
$235.26 - $239.01
52-week range:
$191.97 - $247.99
Dividend yield:
1.21%
P/E ratio:
46.36x
P/S ratio:
1.59x
P/B ratio:
2.44x
Volume:
623.9K
Avg. volume:
508.7K
1-year change:
7.67%
Market cap:
$20B
Revenue:
$12.2B
EPS (TTM):
$5.15
Analysts' Opinion
-
Consensus RatingLabcorp Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $261.36, Labcorp Holdings has an estimated upside of 9.46% from its current price of $238.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $231.00 representing 3.25% downside risk from its current price of $238.77.
Fair Value
-
According to the consensus of 17 analysts, Labcorp Holdings has 9.46% upside to fair value with a price target of $261.36 per share.
LH vs. S&P 500
-
Over the past 5 trading days, Labcorp Holdings has overperformed the S&P 500 by 0.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Labcorp Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Labcorp Holdings has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Labcorp Holdings reported revenues of $3.3B.
Earnings Growth
-
Labcorp Holdings earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Labcorp Holdings reported earnings per share of $2.00.
Enterprise value:
25.2B
EV / Invested capital:
--
Price / LTM sales:
1.59x
EV / EBIT:
30.67x
EV / Revenue:
1.98x
PEG ratio (5yr expected):
--
EV / Free cash flow:
29.91x
Price / Operating cash flow:
23.99x
Enterprise value / EBITDA:
17.49x
Gross Profit (TTM):
$3.5B
Return On Assets:
2.55%
Net Income Margin (TTM):
3.43%
Return On Equity:
5.45%
Return On Invested Capital:
3.23%
Operating Margin:
8.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.8B | $12.1B | $12.7B | $3.1B | $3.3B | |
| Gross Profit | $3.8B | $3.3B | $3.5B | $851.2M | $904.4M | |
| Operating Income | $2.1B | $1.2B | $1.1B | $270M | $272.1M | |
| EBITDA | $2.4B | $1.5B | $1.4B | $434.9M | $422.5M | |
| Diluted EPS | $18.75 | $7.48 | $5.15 | $2.11 | $2.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.1B | $6B | $4.4B | $4B | $4.9B | |
| Total Assets | $18.7B | $20.9B | $19.8B | $16.9B | $18.6B | |
| Current Liabilities | $3B | $2.9B | $2.5B | $2.9B | $3.4B | |
| Total Liabilities | $10.5B | $10.3B | $9.7B | $9B | $10.4B | |
| Total Equity | $8.3B | $10.5B | $10.1B | $7.9B | $8.2B | |
| Total Debt | $5.8B | $5.4B | $5.3B | $5.4B | $6.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2B | $1.4B | $1.4B | $275.5M | $277.3M | |
| Cash From Investing | -$1.6B | -$1.1B | -$1.5B | -$487.6M | -$579.1M | |
| Cash From Financing | -$2B | $14.6M | $880.1M | -$1.1B | $1.5B | |
| Free Cash Flow | $1.6B | $1B | $843.2M | $170.6M | $161.5M | |
LH
Sector
Market Cap
$20B
$45.4M
Price % of 52-Week High
96.28%
46.67%
Dividend Yield
1.21%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
7.67%
-33.9%
Beta (5-Year)
1.060
0.747
Dividend yield:
1.21%
Annualized payout:
$2.88
Payout ratio:
56.05%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$234.50
200-day SMA
Buy
Level
$218.41
Bollinger Bands (100)
Buy
Level
220.78 - 236.9
Chaikin Money Flow
Buy
Level
326.1M
20-day SMA
Buy
Level
$231.16
Relative Strength Index (RSI14)
Buy
Level
62.59
ADX Line
Buy
Level
17.98
Williams %R
Sell
Level
-1.7023
50-day SMA
Buy
Level
$234.77
MACD (12, 26)
Buy
Level
0.95
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
230.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8729)
Buy
CA Score
(Annual)
Level (-0.0768)
Buy
Beneish M-Score
(Annual)
Level (-2.681)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (0.4976)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Stock Forecast FAQ
In the current month, LH has received 10 Buy ratings 7 Hold ratings, and 0 Sell ratings. The LH average analyst price target in the past 3 months is $261.36.
-
Where Will Labcorp Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Labcorp Holdings share price will rise to $261.36 per share over the next 12 months.
-
What Do Analysts Say About Labcorp Holdings?
Analysts are divided on their view about Labcorp Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Labcorp Holdings is a Sell and believe this share price will drop from its current level to $231.00.
-
What Is Labcorp Holdings's Price Target?
The price target for Labcorp Holdings over the next 1-year time period is forecast to be $261.36 according to 17 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is LH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Labcorp Holdings is a Buy. 10 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LH?
You can purchase shares of Labcorp Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Labcorp Holdings shares.
-
What Is The Labcorp Holdings Share Price Today?
Labcorp Holdings was last trading at $238.26 per share. This represents the most recent stock quote for Labcorp Holdings. Yesterday, Labcorp Holdings closed at $238.77 per share.
-
How To Buy Labcorp Holdings Stock Online?
In order to purchase Labcorp Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Why Is Stanley Druckenmiller Buying Citigroup?
As recently as 2020, few analysts could have predicted that…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
NUTX alert for Jan 17
Nutex Health [NUTX] is up 2.83% over the past day.
Buy
53
QMCO alert for Jan 17
Quantum [QMCO] is down 15.61% over the past day.
Sell
34
NGVT alert for Jan 17
Ingevity [NGVT] is up 1.31% over the past day.
